Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
32
NMTC Quote, Financials, Valuation and Earnings
Last price:
$0.70
Seasonality move
:
-23.32%
Day range:
$0.68 - $0.71
52-week range:
$0.40 - $1.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.51x
P/B ratio:
5.35x
Volume:
87.1K
Avg. volume:
267K
1-year change:
-39.29%
Market cap:
$34.3M
Revenue:
$12.1M
EPS (TTM):
-$0.16
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
$2.7M | -- | 75.83% | -57.14% | $2.30 |
|
AORT
Artivion, Inc.
|
$116.4M | $0.18 | 16.97% | -75% | $51.43 |
|
EW
Edwards Lifesciences Corp.
|
$1.5B | $0.62 | 12.89% | 16.77% | $96.50 |
|
NTRB
Nutriband, Inc.
|
$765K | -$0.17 | 4.52% | -54.85% | $15.00 |
|
PETV
PetVivo Holdings, Inc.
|
$350K | -- | 178.67% | -- | -- |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$2.2B | $2.40 | 8.14% | 103.68% | $102.65 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
$0.68 | $2.30 | $34.3M | -- | $0.00 | 0% | 3.51x |
|
AORT
Artivion, Inc.
|
$38.33 | $51.43 | $1.8B | 191.84x | $0.00 | 0% | 4.04x |
|
EW
Edwards Lifesciences Corp.
|
$79.78 | $96.50 | $46.3B | 43.06x | $0.00 | 0% | 7.70x |
|
NTRB
Nutriband, Inc.
|
$4.43 | $15.00 | $53.9M | -- | $0.00 | 0% | 22.11x |
|
PETV
PetVivo Holdings, Inc.
|
$0.70 | -- | $23.5M | -- | $0.00 | 0% | 17.28x |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$98.75 | $102.65 | $19.6B | 27.84x | $0.24 | 0.97% | 2.38x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
3.58% | 2.768 | 0.62% | 4.95x |
|
AORT
Artivion, Inc.
|
36.58% | 2.269 | 11.85% | 1.52x |
|
EW
Edwards Lifesciences Corp.
|
6.42% | -0.006 | 1.21% | 2.86x |
|
NTRB
Nutriband, Inc.
|
3.31% | 2.122 | 0.32% | 7.07x |
|
PETV
PetVivo Holdings, Inc.
|
2.05% | 2.327 | 0.18% | 0.20x |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
37.91% | -0.699 | 43.48% | 0.93x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
$1.6M | -$1.7M | -125.68% | -132.79% | -59.02% | -$3.2M |
|
AORT
Artivion, Inc.
|
$69.7M | $12.5M | 1.44% | 2.6% | 10.76% | -$6.2M |
|
EW
Edwards Lifesciences Corp.
|
$1.2B | $370.3M | 9.63% | 13.19% | 23.59% | $516.2M |
|
NTRB
Nutriband, Inc.
|
$63K | -$3.9M | -159.71% | -164.64% | -1121.15% | -$1.8M |
|
PETV
PetVivo Holdings, Inc.
|
$10K | -$2.2M | -227.61% | -335.08% | -765.99% | -$1.4M |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$1.3B | $282.9M | 3.53% | 5.61% | 12.61% | $358.3M |
NeuroOne Medical Technologies Corp. vs. Competitors
-
Which has Higher Returns NMTC or AORT?
Artivion, Inc. has a net margin of -49.71% compared to NeuroOne Medical Technologies Corp.'s net margin of 2.09%. NeuroOne Medical Technologies Corp.'s return on equity of -132.79% beat Artivion, Inc.'s return on equity of 2.6%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.54.2% -$0.03 $6.6M AORTArtivion, Inc.60.06% $0.05 $706.7M -
What do Analysts Say About NMTC or AORT?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.30, signalling upside risk potential of 238.24%. On the other hand Artivion, Inc. has an analysts' consensus of $51.43 which suggests that it could grow by 34.17%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than Artivion, Inc., analysts believe NeuroOne Medical Technologies Corp. is more attractive than Artivion, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 AORTArtivion, Inc.4 1 0 -
Is NMTC or AORT More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.661, which suggesting that the stock is 33.892% less volatile than S&P 500. In comparison Artivion, Inc. has a beta of 1.591, suggesting its more volatile than the S&P 500 by 59.114%.
-
Which is a Better Dividend Stock NMTC or AORT?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Artivion, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. Artivion, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or AORT?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.9M, which are smaller than Artivion, Inc. quarterly revenues of $116M. NeuroOne Medical Technologies Corp.'s net income of -$1.4M is lower than Artivion, Inc.'s net income of $2.4M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while Artivion, Inc.'s PE ratio is 191.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 3.51x versus 4.04x for Artivion, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.3.51x -- $2.9M -$1.4M AORTArtivion, Inc.4.04x 191.84x $116M $2.4M
-
Which has Higher Returns NMTC or EW?
Edwards Lifesciences Corp. has a net margin of -49.71% compared to NeuroOne Medical Technologies Corp.'s net margin of 4.09%. NeuroOne Medical Technologies Corp.'s return on equity of -132.79% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.54.2% -$0.03 $6.6M EWEdwards Lifesciences Corp.78.3% $0.16 $10.9B -
What do Analysts Say About NMTC or EW?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.30, signalling upside risk potential of 238.24%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $96.50 which suggests that it could grow by 20.96%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than Edwards Lifesciences Corp., analysts believe NeuroOne Medical Technologies Corp. is more attractive than Edwards Lifesciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 EWEdwards Lifesciences Corp.16 12 0 -
Is NMTC or EW More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.661, which suggesting that the stock is 33.892% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.133%.
-
Which is a Better Dividend Stock NMTC or EW?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or EW?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.9M, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. NeuroOne Medical Technologies Corp.'s net income of -$1.4M is lower than Edwards Lifesciences Corp.'s net income of $64.2M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while Edwards Lifesciences Corp.'s PE ratio is 43.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 3.51x versus 7.70x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.3.51x -- $2.9M -$1.4M EWEdwards Lifesciences Corp.7.70x 43.06x $1.6B $64.2M
-
Which has Higher Returns NMTC or NTRB?
Nutriband, Inc. has a net margin of -49.71% compared to NeuroOne Medical Technologies Corp.'s net margin of -1118.87%. NeuroOne Medical Technologies Corp.'s return on equity of -132.79% beat Nutriband, Inc.'s return on equity of -164.64%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.54.2% -$0.03 $6.6M NTRBNutriband, Inc.18.2% -$0.32 $7.8M -
What do Analysts Say About NMTC or NTRB?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.30, signalling upside risk potential of 238.24%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 238.6%. Given that Nutriband, Inc. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe Nutriband, Inc. is more attractive than NeuroOne Medical Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 NTRBNutriband, Inc.1 0 0 -
Is NMTC or NTRB More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.661, which suggesting that the stock is 33.892% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.886, suggesting its more volatile than the S&P 500 by 88.601%.
-
Which is a Better Dividend Stock NMTC or NTRB?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NTRB?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.9M, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. NeuroOne Medical Technologies Corp.'s net income of -$1.4M is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 3.51x versus 22.11x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.3.51x -- $2.9M -$1.4M NTRBNutriband, Inc.22.11x -- $346.1K -$3.9M
-
Which has Higher Returns NMTC or PETV?
PetVivo Holdings, Inc. has a net margin of -49.71% compared to NeuroOne Medical Technologies Corp.'s net margin of -765.99%. NeuroOne Medical Technologies Corp.'s return on equity of -132.79% beat PetVivo Holdings, Inc.'s return on equity of -335.08%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.54.2% -$0.03 $6.6M PETVPetVivo Holdings, Inc.3.5% -$0.07 $3.4M -
What do Analysts Say About NMTC or PETV?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.30, signalling upside risk potential of 238.24%. On the other hand PetVivo Holdings, Inc. has an analysts' consensus of -- which suggests that it could grow by 614.29%. Given that PetVivo Holdings, Inc. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe PetVivo Holdings, Inc. is more attractive than NeuroOne Medical Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 PETVPetVivo Holdings, Inc.0 0 0 -
Is NMTC or PETV More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.661, which suggesting that the stock is 33.892% less volatile than S&P 500. In comparison PetVivo Holdings, Inc. has a beta of 0.306, suggesting its less volatile than the S&P 500 by 69.424%.
-
Which is a Better Dividend Stock NMTC or PETV?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PetVivo Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. PetVivo Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or PETV?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.9M, which are larger than PetVivo Holdings, Inc. quarterly revenues of $286.1K. NeuroOne Medical Technologies Corp.'s net income of -$1.4M is higher than PetVivo Holdings, Inc.'s net income of -$2.2M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while PetVivo Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 3.51x versus 17.28x for PetVivo Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.3.51x -- $2.9M -$1.4M PETVPetVivo Holdings, Inc.17.28x -- $286.1K -$2.2M
-
Which has Higher Returns NMTC or ZBH?
Zimmer Biomet Holdings, Inc. has a net margin of -49.71% compared to NeuroOne Medical Technologies Corp.'s net margin of 6.15%. NeuroOne Medical Technologies Corp.'s return on equity of -132.79% beat Zimmer Biomet Holdings, Inc.'s return on equity of 5.61%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.54.2% -$0.03 $6.6M ZBHZimmer Biomet Holdings, Inc.56.23% $0.70 $20.5B -
What do Analysts Say About NMTC or ZBH?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.30, signalling upside risk potential of 238.24%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.65 which suggests that it could grow by 3.95%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe NeuroOne Medical Technologies Corp. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 ZBHZimmer Biomet Holdings, Inc.6 17 2 -
Is NMTC or ZBH More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.661, which suggesting that the stock is 33.892% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.12%.
-
Which is a Better Dividend Stock NMTC or ZBH?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 0.97% to investors and pays a quarterly dividend of $0.24 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 27.05% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NMTC or ZBH?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.9M, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2.2B. NeuroOne Medical Technologies Corp.'s net income of -$1.4M is lower than Zimmer Biomet Holdings, Inc.'s net income of $137.9M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while Zimmer Biomet Holdings, Inc.'s PE ratio is 27.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 3.51x versus 2.38x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.3.51x -- $2.9M -$1.4M ZBHZimmer Biomet Holdings, Inc.2.38x 27.84x $2.2B $137.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 23
RingCentral, Inc. [RNG] is down 10.56% over the past day.
Sell
9
FROG alert for Feb 23
JFrog Ltd. [FROG] is down 6.15% over the past day.
Buy
72
SNSE alert for Feb 23
Sensei Biotherapeutics, Inc. [SNSE] is up 1.16% over the past day.
